5 Pharmaceutical Stocks to Buy According to Brandon Haley’s Holocene Advisors

2. Mirati Therapeutics, Inc. (NASDAQ:MRTX)

Holocene Advisors’ Stake Value: $140 million

Percentage of Holocene Advisors’ 13F Portfolio: 0.76%

Number of Hedge Fund Holders: 46

Mirati Therapeutics, Inc. (NASDAQ:MRTX) is a clinical level therapeutics and pharmaceutical company based in California, US. It is focused on finding breakthrough medical solutions to cancer. Holocene Advisors owns nearly 0.8 million shares in the company after a 10% stake-increase in the third quarter of 2021.

BMO Capital analyst Evan Seigerman initiated the coverage of Mirati Therapeutics, Inc. (NASDAQ:MRTX) with an ‘Outperform’ rating and a price target of $187. The analyst said his rating is based on his view that adagrasib is a better inhibitor than KRAS G12C; that Lumakras’ first move advantage is most likely short-lived; a promising pipeline with a unique inhibitor to KRAS G12D; and the potential that Mirati Therapeutics, Inc. (NASDAQ:MRTX) would be an “attractive” acquisition candidate for a bigger biopharma company.